Live News

Gepirone Extended-Release: First Approval

Gepirone HCL extended-release (gepirone ER; EXXUA™), an oral, selective serotonin (5HT)1A receptor agonist formulate...

New Therapies on the Horizon for Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that can progress to cirrhosis and hepatic failur...

Drugs

0 0

Zilucoplan: First Approval

Zilucoplan (Zilbrysq®) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 i...

Drugs

0 0

Vamorolone: First Approval

Vamorolone (AGAMREE®) is an oral, selective, dissociative corticosteroid developed by ReveraGen BioPharma and Santher...

Drugs

0 0

Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis

Temporomandibular disorders (TMD) comprise a cluster of conditions with a wide range of etiological factors that causes pa...

Drugs

0 0

Reply to the Comments on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”

Funding The original article was supported by funding from Chung Sh...

Drugs

0 0

Comment on: “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”

Conflict of interest TWC and C-HH declare that they have no competi...

Drugs

0 0

Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies

Kirsten rat sarcoma virus (KRAS) is one of the most important and frequently mutated oncogenes in cancer and the mutationa...

Drugs

0 0

Narlumosbart: First Approval

Narlumosbart (津立生) is a recombinant, fully human, anti-receptor activator of nuclear factor kappa- ...

Drugs

0 0

Spesolimab for the Treatment of Generalized Pustular Psoriasis

Generalized pustular psoriasis (GPP) is a rare but severe skin inflammatory disorder characterized by the eruption of wide...

Drugs

0 0

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity h...

Drugs

0 0

Correction to: Motixafortide: First Approval

In the published PDF version, Section 2.1 Pharmacodynamics, second paragraph, sixth s...

Drugs

0 0

Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension

A randomized, double-masked, multicenter, phase 2 trial to evaluate the long-term safety and efficacy of travoprost intrao...

Drugs

0 0

Nedosiran: First Approval

Nedosiran (RIVFLOZA™), a once-monthly subcutaneous small interfering RNA (siRNA) therapy, is being developed by Dice...

Drugs

0 0

Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage

With the worldwide approval of the oral covalent Bruton tyrosine kinase (BTK) inhibitors ibrutinib and zanubrutinib for tr...

Drugs

0 0

Iruplinalkib: First Approval

Iruplinalkib (Trade name: 启欣可®; Code name: WX-0593), a highly selective oral anaplastic lymphoma...

Drugs

0 0

Momelotinib: First Approval

Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that ha...

Drugs

0 0

Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults

Mitapivat (Pyrukynd®), an oral, allosteric activator of pyruvate kinase (PK), is approved in the USA for the treatmen...

Drugs

0 0

Motixafortide: First Approval

Motixafortide (APHEXDATM) is a selective C-X-C motif chemokine receptor 4 (CXCR4) inhibitor being developed by BioLineRx u...

Drugs

0 0

Correction: Elacestrant: First Approval

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...

Drugs

0 0

Sunvozertinib: First Approval

Sunvozertinib (舒沃哲®) is an oral, irreversible, epidermal growth factor receptor (EGFR) tyrosine ...

Drugs

0 0

Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM

The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (E/T/I) has...

Drugs

0 0

Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 Internationa...

Drugs

0 0

Current and Emerging Treatment Options for Uterine Fibroids

Uterine fibroids are the most common benign neoplasm of the female reproductive tract in reproductive age women. Their pre...

Drugs

0 0

Elranatamab: First Approval

Elranatamab (elranatamab-bcmm; ELREXFIO™) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engag...

Drugs

0 0

Correction to: Rozanolixizumab: First Approval

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...

Drugs

0 0

Zuranolone: First Approval

Zuranolone (ZURZUVAE™) is an oral neuroactive steroid and a positive allosteric modulator of the gamma aminobutyric ...

Drugs

0 0

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis is complex and encompasses mult...

Drugs

0 0

Lotilaner Ophthalmic Solution 0.25%: First Approval

Lotilaner ophthalmic solution 0.25% (XDEMVY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor ...

Drugs

0 0

Tafolecimab: First Approval

Tafolecimab (SINTBILO®), a subcutaneously administered anti-proprotein convertase subtilisin/kexin type 9 enzyme&...

Drugs

0 0

Categories

Channels

SCI Abstract